| Drug General Information |
| Drug ID |
D0Z7OX
|
| Former ID |
DIB020284
|
| Drug Name |
LY-465608
|
| Synonyms |
LY465608; LY 465608
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C28H27NO5
|
| InChI |
InChI=1S/C28H27NO5/c1-19-25(17-18-32-23-13-15-24(16-14-23)34-28(2,3)27(30)31)29-26(33-19)22-11-9-21(10-12-22)20-7-5-4-6-8-20/h4-16H,17-18H2,1-3H3,(H,30,31)
|
| InChIKey |
JDJHTJNBMZSSLK-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14857992, 22395220, 24176039, 45637255, 57373695, 77734461, 103194867, 103853900, 103997212, 109614339, 135650557, 142114883, 152186759, 223798975, 232392692, 247402069
|
| Target and Pathway |
| Target(s) |
mRNA of PPAR-gamma |
Target Info |
Agonist |
[2]
|
|---|
| Peroxisome proliferator activated receptor alpha |
Target Info |
Agonist |
[3]
|
|
KEGG Pathway
|
PPAR signaling pathway
|
|
AMPK signaling pathway
|
|
Osteoclast differentiation
|
|
Huntington's disease
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Thyroid cancerhsa03320:PPAR signaling pathway
|
|
cAMP signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Glucagon signaling pathway
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Hepatitis C
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
PANTHER Pathway
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Noncanonical Wnt signaling pathway
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Signaling events mediated by HDAC Class I
|
|
RXR and RAR heterodimerization with other nuclear receptor
|
|
Regulation of retinoblastoma proteinrxr_vdr_pathway:RXR and RAR heterodimerization with other nuclear receptor
|
|
Reactome
|
PPARA activates gene expression
|
|
Transcriptional regulation of white adipocyte differentiation
|
|
Nuclear Receptor transcription pathwayR-HSA-1368082:RORA activates gene expression
|
|
BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
|
YAP1- and WWTR1 (TAZ)-stimulated gene expression
|
|
Transcriptional activation of mitochondrial biogenesis
|
|
Activation of gene expression by SREBF (SREBP)
|
|
Nuclear Receptor transcription pathway
|
|
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Circadian Clock
|
|
WikiPathways
|
Wnt Signaling Pathway Netpath
|
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Differentiation of white and brown adipocyte
|
|
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
Adipogenesis
|
|
SREBP signalling
|
|
Nuclear ReceptorsWP299:Nuclear Receptors in Lipid Metabolism and Toxicity
|
|
Nuclear Receptors Meta-Pathway
|
|
Estrogen Receptor Pathway
|
|
PPAR Alpha Pathway
|
|
YAP1- and WWTR1 (TAZ)-stimulated gene expression
|
|
Activation of Gene Expression by SREBP (SREBF)
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
Circadian Clock
|
|
Nuclear Receptors
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2659). |
|---|
| REF 2 | Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. J Med Chem. 2001 Jun 21;44(13):2061-4. |
|---|
| REF 3 | Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists. J Med Chem. 2004 May 6;47(10):2422-5. |
|---|
